We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App

Noninvasive Technology Detects Rare Cancer Cells in Blood

By LabMedica International staff writers
Posted on 10 Jun 2024
Print article
Image: DiFC detects cancer cells expressing fluorescent proteins when cells are excited by laser light as they move through a blood vessel (Photo courtesy of Williams et al., doi 10.1117/1.JBO.29.6.065003)
Image: DiFC detects cancer cells expressing fluorescent proteins when cells are excited by laser light as they move through a blood vessel (Photo courtesy of Williams et al., doi 10.1117/1.JBO.29.6.065003)

Historically, analyzing circulating tumor cells (CTCs) required invasive methods like blood draws, which often missed rare CTCs or multicellular CTC clusters (CTCCs) known for their high metastatic potential. Now, a groundbreaking technology offers a new way for researchers to monitor and understand the spread of cancer within the body.

A collaborative effort between researchers at Northeastern University (Boston, MA, USA) and Dartmouth College (Hanover, NH, USA) has led to the development of an innovative device known as "diffuse in vivo flow cytometry" (DiFC). This technology facilitates the noninvasive detection and counting of rare cancer cells circulating in the bloodstream. By utilizing highly scattered light to probe large blood vessels, DiFC overcomes the shortcomings of traditional tests to enable the noninvasive analysis of larger peripheral blood volumes and detection of rare cancer cells. The team’s pioneering two-color DiFC system can simultaneously identify two distinct populations of cancer cell in real time within small animals, paving the way for deeper insights into cancer evolution and treatment responses by studying various cancer cell subpopulations in the same subject.

The versatility of this two-color DiFC system was demonstrated through experiments on tissue-mimicking flow phantoms and mice afflicted with multiple myeloma. By effectively distinguishing cancer cells marked by green fluorescent protein (GFP) and tdTomato, it was possible to observe the dynamics of cancer spread in real time. Notably, most detected CTCCs exhibited single fluorescent proteins, shedding light on the heterogeneity of cancer cell populations. The implications of this technology are significant as it offers the potential to simultaneously track various subpopulations of cancer cells, providing critical insights into tumor growth and therapeutic responses. This paves the way for more refined and individualized treatment options, moving closer to effectively managing cancer. While the battle against cancer is complex, advancements like DiFC provide the tools essential for meeting this challenge. As this technology evolves, it promises to lead to more effective cancer therapies and a future where cancer may no longer be a life-threatening condition. 

Related Links:
Northeastern University
Dartmouth College

Print article


Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.